Characteristics and Predictors of Ovarian Cancer of Inpatients in USA
DOI:
https://doi.org/10.668995/rfs9bb36Keywords:
Ovarian cancer, gynecologic cancer, Congestive heart failure, hypertension, ascites, comorbiditiesAbstract
Ovarian cancer is the second most common type of gynecologic cancer, and it causes more death than any other female reproductive cancer. It is the 7th most common women's cancer. The objective of the present study is to highlight the risk factors of ovarian cancer related to hospitalization outcomes such as mortality, length of stay, and total medical charges when there is a presence of Congestive heart failure and other complications. Statistical Package for the Social Sciences (SPSS) version 28.0 was used to analyze the present study's data, and all outcomes with a p-value less than 0.05 were found to be significant. Overall mortality showed a higher incidence of epithelial ovarian cancer. Patients with HT had a higher death rate with epithelial ovarian cancer than CHF. Increasing age and being white results in an average in length of stay. Those patients with weight loss comorbidities resulted in the greatest mean increase in length of stay. Hispanic population results in an average increase in total cost, while, whites and blacks results in lower cost. The deceased risk of dying was associated with the number of procedures. Increased age and number of diagnoses were associated with an increased likelihood of dying. The increase in procedures and SES increases the length of stay. Among those with hypertension, these predictors are significantly higher. The predictors of mortality assessed by age and number of diseases, which were associated with an increased likelihood of dying.
Downloads
References
1. Ahmed N, Kadife E, Raza A, Short M, Jubinsky PT, Kannourakis G. Ovarian cancer, cancer stem cells, and current treatment strategies: a potential role of magmas in current treatment methods. Cells. 2020;9(3):719. doi:10.3390/cells9030719
2. Armbrust R, Wimberger P, Mustea A, Oskay-Özcelik G, Keller M, Richter R, et al. Effect of hypertension on progression-free survival in patients receiving front-line bevacizumab for primary advanced ovarian cancer: NOGGO OTILIA study post hoc analysis. J Clin Oncol. 2018;36(15_suppl):5546.
3. Arora N, Talhouk A, McAlpine JN, Law MR, Hanley GE. Long-term mortality among women with epithelial ovarian cancer: a population-based study. BMC Cancer. 2018;18(1):4970. doi:10.1186/s12885-018-4970-9
4. Bouchard-Fortier G, Cusimano MC, Fazelzad R, Sajewycz K, Lu L, Espin-Garcia O, et al. Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2020;158(1):218-28. doi:10.1016/j.ygyno.2020.03.034
5. Bulun SE, Wan Y, Matei D. Epithelial mutations in endometriosis: link to ovarian cancer. Endocrinology. 2019;160(3):626-38. doi:10.1210/en.2018-00794
6. Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, et al. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol. 2011;204(4):355.e1-7.
7. Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1. J Am Coll Cardiol. 2017;70(20):2536-51. doi:10.1016/j.jacc.2017.09.1096
8. Chang LC, Huang CF, Lai MS, Shen LJ, Wu FLL, Cheng WF. Prognostic factors in epithelial ovarian cancer: a population-based study. PLoS One. 2018;13(3):e0194993. doi:10.1371/journal.pone.0194993
9. Chiofalo B, Bruni S, Certelli C, Sperduti I, Baiocco E, Vizza E. Primary debulking surgery vs interval debulking surgery for advanced ovarian cancer: a meta-analysis. Minerva Med. 2019;110(4):330-40. doi:10.23736/S0026-4806.19.06078
10. Cho MA, Kim JH, Kim S, Song YS. Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation. Chin Clin Oncol. 2018;7(6):58. doi:10.21037/cco.2018.10.11
11. Cho MA, Jeong SY, Sohn I, Kim MS, Kang JH, Paik ES, et al. Impact of antihypertensive drugs on survival of ovarian cancer patients. Cancer Res Treat. 2020;52(2):645-53. doi:10.4143/crt.2019.509
12. Chovanec M, Zaid MA, Hanna N, El-Kouri N, Einhorn LH, Albany C. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol. 2017;28(11):2670-9. doi:10.1093/annonc/mdx360
13. Coleman RL, Liu J, Matsuo K, Thaker PH, Westin SN, Sood AK. Carcinoma of the ovaries and fallopian tubes. In: Abeloff MD, editor. Abeloff’s Clinical Oncology. Elsevier; 2020. p. 1525-43. doi:10.1016/B978-0-323-47674-4.00086-4
14. Crosbie EJ, Ryan NAJ, McVey RJ, Lalloo F, Bowers N, Green K, et al. Assessment of mismatch repair deficiency in ovarian cancer. J Med Genet. 2021;58:687-91. doi:10.1136/jmedgenet-2020-107270
15. Daniele G, Raspagliesi F, Scambia G, Pisano C, Colombo N, Frezzini S, et al. Bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced ovarian cancer: MITO-16A study. Int J Gynecol Cancer. 2021;31(6). doi:10.1136/ijgc-2021-002434
16. Derquin F, Floquet A, Hardy-Bessard AC, Edeline J, Lotz JP, Alexandre J, et al. Risk-adapted therapy for malignant ovarian germ cell tumors. Gynecol Oncol. 2020;158(3):666-72. doi:10.1016/j.ygyno.2020.06.491
17. Dixon C, Herbert DL, Loxton D, Lucke JC. Contraceptive use and barriers among Australian women. Eur J Contracept Reprod Health Care. 2014;19(5):340-51. doi:10.3109/13625187.2014.919380
18. Foong KW, Bolton H. Obesity and ovarian cancer risk: a systematic review. Post Reprod Health. 2017;23(4):183-98. doi:10.1177/2053369117709225
19. Grossman DC, Curry SJ, Owens DK, Barry MJ, Davidson KW, Doubeni CA, et al. Screening for ovarian cancer: USPSTF recommendation statement. JAMA. 2018;319(6):588-94. doi:10.1001/jama.2017.21926
20. Iversen L, Fielding S, Lidegaard Ø, Mørch LS, Skovlund CW, Hannaford PC. Hormonal contraception and ovarian cancer risk: cohort study. BMJ. 2018;362:k3609. doi:10.1136/bmj.k3609
21. Khazaei Z, Namayandeh SM, Beiranvand R, Naemi H, Bechashk SM, Goodarzi E. Worldwide incidence and mortality of ovarian cancer. J Prev Med Hyg. 2021;62(1):E174. doi:10.15167/2421-4248/jpmh2021.62.1.1606
22. Menon U, Karpinskyj C, Gentry-Maharaj A. Ovarian cancer prevention and screening. Obstet Gynecol. 2018;131(5):909-27. doi:10.1097/AOG.0000000000002580
23. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer epidemiology and risk factors. Int J Womens Health. 2019;11:287-99. doi:10.2147/IJWH.S197604
24. Park IS, Kim SI, Han Y, Yoo J, Seol A, Jo H, et al. Obesity and female-specific cancer risk. Lancet Reg Health West Pac. 2021;11:100146. doi:10.1016/j.lanwpc.2021.100146
25. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9-32. doi:10.20892/j.issn.2095-3941.2016.0084
26. Rosenthal AN, Fraser LS, Philpott S, Manchanda R, Burnell M, Badman P, et al. Stage shift in ovarian cancer screening study. J Clin Oncol. 2017;35(13):1411. doi:10.1200/JCO.2016.69.9330
27. Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151-6. doi:10.1016/j.soncn.2019.02.001
28. Temkin SM, Mallen A, Bellavance E, Rubinsak L, Wenham RM. Menopausal hormone therapy and cancer risk. Cancer. 2019;125(4):499-514.
29. Torng PL. Endometriosis associated with ovarian cancer. Gynecol Minim Invasive Ther. 2017;6(4):152-6. doi:10.1016/j.gmit.2017.08.003
30. Verdoodt F, Hansen MK, Kjaer SK, Pottegård A, Friis S, Dehlendorff C. Statin use and ovarian cancer mortality. Int J Cancer. 2017;141(2):279-86. doi:10.1002/ijc.30738
31. Zhang X, Li H, Yu X, Li S, Lei Z, Li C, et al. Circulating tumor cells in ovarian cancer. Cell Physiol Biochem. 2019;48(5):1983-94. doi:10.1159/000492521
32. Zhang GQ, Chen JL, Luo Y, Mathur MB, Anagnostis P, Nurmatov U, et al. Menopausal hormone therapy: umbrella review. PLoS Med. 2021;18(8):e1003731.
Additional Files
Published
Issue
Section
License
Copyright (c) 2026 Sneha Chidambaran (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in the Virosa Journal of AI in Science and Healthcare (VJASH) are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
This license allows:
-
Sharing – copying and redistributing the material in any medium or format
-
Adaptation – remixing, transforming, and building upon the material for any purpose, even commercially
Under the following conditions:
-
Attribution – appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and indication must be made if changes were made.
-
No additional restrictions – you may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
By publishing with VJASH, authors:
-
Retain the full copyright of their work.
-
Grant the journal the right of first publication.
-
Agree that their article will be published and distributed under the CC BY 4.0 license.
The full legal code of the license is available here: https://creativecommons.org/licenses/by/4.0/
